Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Sep 25, 2024 02:08PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
It is surprising that Zenith is only going for an Equity Private Placement valued at $8M US.
Min subscription of $50K US to institutional and accredited investors.
The price per unit is 60 cents US with a 2-year warrant at 75 cents US.
As I understand it this adds 13.333 Million common shares to ZCC. The Proceeds for continuing oncology clinical development and for RVX apabatelone commercializing efforts.
Koo